Viral Gene Therapy Market Scope
Modified viruses are used as drug delivery vehicles to insert particular DNA sequences—encoding genes, regulatory RNAs, or other therapeutic substrates—into cells in viral-vector gene treatments. Gene therapies are potential treatments for a wide range of disorders, with the goal of fundamentally treating the diseases' origins rather than just alleviating the symptoms. They might help with a variety of previously treatable illnesses, including hematological, ophthalmic, neurological, and malignancies.
Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Viral Gene Therapy market throughout the predicted period.
Biogen (United States), Novartis AG (Switzerland), Gilead Sciences, Inc. (United States), Spark Therapeutics, Inc. (United States), Orchard Therapeutics plc. (United Kingdom), MolMed S.p.A. (Italy), AnGes, Inc. (Japan), Bluebird bio, Inc. (United States), Human Stem Cells Institute (Russia) and Dynavax Technologies (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Akcea Therapeutics (United States), Alnylam Pharmaceuticals, Inc. (United States) and Jazz Pharmaceuticals, Inc. (Ireland).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
The study have segmented the market of Global Viral Gene Therapy market and Region with country level break-up.
On the basis of geography, the market of Viral Gene Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
On 15 April 2019, Catalent acquire gene therapy leader Paragon Bioservices. This acquisition helps the company by transformative addition. Paragon offers an additional capacity to Catalent that will significantly improve our biologics business and end-to-end integrated biopharmaceutical solutions for clients. Paragon has unique skills in GMP plasmids and lentivirus vectors, as well as specific knowledge in adeno-associated virus (AAV) vectors, the most widely utilized delivery mechanism for gene therapy.
On 24 May 2019, AveXis, a Novartis company announced the approval of Zolgensma by USFDA for the treatment of pediatric patients less than 2 years of age suffering with spinal muscular atrophy with a bi-allelic mutation in the survival motor neuron gene. With a single, one-time intravenous infusion, Zolgensma is aimed to treat the genetic root cause of SMA by delivering a functional copy of the human SMN gene to prevent disease development through sustained SMN protein production. The FDA has authorized Zolgensma as the first and only gene therapy for the treatment of SMA, including those who are pre-symptomatic at the time of diagnosis.
“As per USFDA for therapeutic reasons, human gene therapy seeks to change the biological properties of live cells or modify the expression of a gene. All products that mediate their effects by transcription or translation of transferred genetic information or by explicitly changing host (human) genetic sequences are considered human gene therapy products by the FDA. Nucleic acids genetically modified microorganisms (e.g., viruses, bacteria, fungus), designed site-specific nucleases used for human genome editing, and ex vivo genetically changed human cells are all examples of gene therapy products. It should include a broad overview of the gene therapy product under research, as well as a description of the active ingredient(s), mechanism of action, and intended clinical use.”
- Technological Advancement of Editing and Genome Therapy in Molecular and Cell Biology
- Demand for Viral Gene Therapy for the Treatment of Cancer and Neurosurgical Disease
- Approval of Products Such as Zolgensma And Lentiglobin will propel the Viral Gene Therapy Market
- Large Number of Medicines Currently Undergoing Clinical Testing and Government Investment in Gene Therapy Market Will Boost the Viral Gene Therapy Market
- High Cost of Gene Treatments and Undesired Immune Reactions Will Constrain the Viral Gene Therapy Market
- Infection and Possibilities of Tumor During Viral Gene Therapy is Challenge for the Viral Gene Therapy Market
Key Target Audience
Viral Gene Therapy Providers, Research and Development Institutes, Upstream and Downstream Buyers, Financial Institutes and Investors, Regulatory Bodies and Others